(Reuters) – Johnson & Johnson (N:) reported a 1.7% rise in third-quarter sales on Tuesday due to higher demand for its cancer drugs, a day after the company said it had paused its COVID-19 vaccine trials.
The healthcare conglomerate late Monday said it had temporarily paused its COVID-19 vaccine candidate clinical trials due to an unexplained illness in a study participant, delaying one of the highest profile efforts to contain the global pandemic.
Quarterly sales rose to $21.08 billion from $20.73 billion.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.